These 4 Healthcare Stocks Healthy With Potential Opportunities
CORAL GABLES, FL / ACCESSWIRE / January 29, 2019 / The healthcare stock market has increasingly attracted more attention over the last few months, as more companies have focused their efforts on developing new treatment options for patients suffering from a myriad of diseases. Given that the life-force of the industry is dependent on companies creating innovative treatments and products to better improve the quality of life for consumers, any company wishing to rise above the rest need only prove that their products can make visceral changes for patients. With headlines popping up left and right, news surrounding these innovative companies in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), OncoCyte Corp (NYSE American: OCX), Neovasc Inc (NVCN), Zynerba Pharmaceuticals Inc (ZYNE) represent four healthcare companies working tirelessly to champion treatment solutions for the betterment of humankind.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.
Over the course of the last few months, the Company has seen impressive gains as investors and consumers have understood just how far Premier will go, in terms of making strategic investments to offer top-of-the-line products and treatments for its patients.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) today announced that further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.
Per the official details of the agreement, Premier will pay to the Cloud Practice shareholders total consideration of up to $5 million, $2 million dollars in cash to be paid out as follows: (i) $500,000 paid in cash on signing of the binding LOI as a refundable deposit, (ii) $500,000 in cash payable on closing, (iii) $500,000 in cash payable 90 days after closing, (iv) $500,000 in cash payable within six months of the LOI subject to the satisfaction of certain milestones related to the integration of the Juno EMR, and $3 million payable in common shares of Premier at a deemed price of $0.76 per share.
Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI), commented, ''we are very excited to have completed this acquisition and to have the experienced team at Cloud Practice join the team at Premier Health. With this acquisition, we now have a medical software company with national reach. Thus, enabling us to build on our patient-centric technology platform that will integrate telemedicine, online booking and other premium services with our electronic medical records (EMR) system.''
For More Information On Premier Health Group, Click Here
OncoCyte Corp (OCX), a developer of non-invasive tests for the early detection of cancer, made headlines today when the Company announced positive results from its recent R&D Validation study demonstrating the accuracy of the Company's DetermaVuâ„¢ liquid biopsy test for lung cancer.
Following the Company's announcement, Lyndal Hesterberg, Ph.D., Senior Vice President of Research and Development of OncoCyte, stated, ''These results serve to validate OncoCyte's immune system interrogation approach and are a significant scientific advancement in the field of liquid biopsy with three main achievements: First, we have demonstrated that the biological basis for DetermaVuâ„¢, that is, gene expression changes within the immune system in response to cancer, can serve as a highly sensitive and accurate signal in blood for early-stage lung cancer diagnosis.
For More Information On OncoCyte Corp, Click Here
Neovasc Inc (NVCN) today announced that it has completed the Phase 1 requirements of the TIARA-II study required by the bi-phasic study design in both Germany and the United Kingdom and has received approval to proceed with Phase 2 of the TIARA-II study for its Tiaraâ„¢ transcatheter mitral valve replacement device. This approval comes following Clinical Events Committee adjudication of adverse events, Data and Safety Monitoring Board review of the data, and Governmental regulatory and ethics committees reviews of the interim clinical report provided for 20 implanted subjects.
Fred Colen, Neovasc's President, and CEO, commented, ''the Neovasc team is excited about the positive news from the governmental healthcare authorities in Germany and the UK, as well as from the independent ethics committees in both countries. After their review of the submitted, detailed results of the first 20 Tiara implants, we received all required approvals to continue this TIARA-II clinical study into the second and final phase of full enrollment, without further restrictions.''
For More Information on Neovasc Inc, Click Here
Zynerba Pharmaceuticals Inc (ZYNE), a leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, reported in mid-December 2018 reported new 12-month open-label clinical data describing the long term impact of ZYN002 on emotional and behavioral symptoms of Fragile X Syndrome (FXS) in a poster presentation at the 57th Annual Meeting of the American College of Neuropsychopharmacology.
According to the details of the announcement at the time, Steven Siegel, M.D., Ph.D., Professor and Chair of the Department of Psychiatry and the Behavioral Sciences at the Keck School of Medicine, University of Southern California, would be responsible for delivering the presentation.
For More Information On Zynerba Pharmaceuticals Inc, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for & were paid ''500,000'' shares of restricted common shares (as of 1/29/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information Please click here for full disclaimer.
Contact Information:
SOURCE: StockPrice.com
